MS: Busting the Myths
November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
November 16, 2022 | Advocacy, Covid-19, Treatments
Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]
September 14, 2022 | Advocacy, Treatments
Autologous Hematopoietic Stem Cell Treatment (aHSCT) is an intense chemotherapy treatment which aims to wipe out harmful immune cells and rebuild the immune system. aHSCT is a life-improving treatment halting the disease and disability in its tracks. A person receiving […]
September 14, 2022 | Advocacy, Progressive, Treatments
Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]
July 26, 2022 | Advocacy, Life with MS, Media, Treatments
A 10,000-strong petition asking Health New Zealand to extend “game-changing” stem cell treatment to multiple sclerosis (MS) patients is set to be delivered to Parliament. The petition started by Aucklander Joan Perry, whose daughter Anne Besley has MS, calls for autologous haematopoietic […]